Key result
Ivabradine successfully controlled recalcitrant ectopic atrial tachycardia as an adjunct therapy in a critically ill neonate with complex congenital heart disease, though it caused chronotropic insufficiency requiring atrial pacing.
Why the study?
Ivabradine lowers heart rate with minimal effect on blood pressure or inotropy, but its use in pediatric populations is limited.
Case Report (n=1)
No
This case report highlights the potential use of ivabradine for managing recalcitrant ectopic atrial tachycardia in a critically ill pediatric patient with complex congenital heart disease.
Case experience supports neonatal ivabradine use; leaves open prospective validation before practice change.
Ivabradine is the only hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor currently approved for use in the United States. It decreases heart rate with minimal effect on blood pressure or inotropy, making it an attractive agent with an overall low side effect profile. The use of ivabradine in the pediatric population is limited, with current approvals only for dilated cardiomyopathy patients.1 Recent literature has supported the use of ivabradine in neonatal patients with junctional ectopic tachycardia.
No takes yet. Share an insight, caveat, or question.
Hackett et al. (2022) conducted a case report in Recalcitrant ectopic atrial tachycardia and complex congenital heart disease (n=1). Ivabradine was evaluated on Control of ectopic atrial tachycardia. Ivabradine successfully controlled recalcitrant ectopic atrial tachycardia as an adjunct therapy in a critically ill neonate with complex congenital heart disease, though it caused chronotropic insufficiency requiring atrial pacing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: